Edwards Lifesciences Corp

For the period ended Dec 31, 2023. Filed Feb 12, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 12, 2024

EW$104.71+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(in millions, except per share information)

	Years Ended December 31,
	2023	2022	2021
Net sales	$6,004.8	$5,382.4	$5,232.5
Cost of sales	1,379.8	1,080.4	1,248.9
Gross profit	4,625.0	4,302.0	3,983.6
Selling, general, and administrative expenses	1,824.6	1,567.6	1,493.7
Research and development expenses	1,071.8	945.2	903.1
Intellectual property agreement and litigation expense (Note 3)	203.5	15.8	20.6
Change in fair value of contingent consideration liabilities (Note 12)	(26.2)	(35.8)	(124.1)
Special charge and separation costs (Note 4)	17.2	60.7	—
Operating income	1,534.1	1,748.5	1,690.3
Interest expense	17.6	19.2	18.4
Interest income	(67.2)	(35.5)	(17.4)
Other income, net (Note 17)	(14.4)	(2.6)	(12.7)
Income before provision for income taxes	1,598.1	1,767.4	1,702.0
Provision for income taxes (Note 18)	198.7	245.5	198.9
Net income	1,399.4	1,521.9	1,503.1
Net loss attributable to noncontrolling interest (Note 9)	(3.0)	—	—
Net income attributable to Edwards Lifesciences Corporation.	$1,402.4	$1,521.9	$1,503.1
Share information (Note 2):
Earnings per share attributable to Edwards Lifesciences Corporation:
Basic	$2.31	$2.46	$2.41
Diluted	$2.30	$2.44	$2.38
Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation:
Basic	606.7	619.0	623.3
Diluted	609.4	624.2	631.2

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.